ÌÇÐÄÆƽâ°æ

According to the estimates of the World Health Organization and the UNICEF, China has achieved over 96 percent coverage rates for 12 different vaccines in 2022. The coverage of the Bacillus Calmette–Guérin (BCG) vaccine, primarily used against tuberculosis, has remained at 99 percent.

Present state of the market

Until recently, foreign pharmaceutical companies were required to conduct clinical trials in China before they could manufacture the a vaccine for the Chinese market. However, in 2017, the Chinese Food and Drug Administration (CFDA) relaxed the aforementioned requirement to improve the ease of doing business with foreign vaccine manufacturing companies. The response of the vaccine producing market to this regulation change was positive, resulting in an almost immediate expansion of the sector. Even though foreign participants were now able to access the market with more ease, domestic manufacturing of vaccines still accounted for a vast majority of the vaccines produced in China.

Moving on from the one-child policy

In 2018, China had a birth rate of approximately four times that of the USA, which has been further boosted by the relaxation of the one-child policy in China. Along with China’s commitment to universal vaccination of infants, it is likely that the market for immunizations only keep growing.